简介：Acrucialfeatureofnanoparticles,suchasliposomes,magneticnanoparticles,quantumdots,metallicnanoparticles,silicananoparticles,polymersomesanddendrimersetc.,istheirhigheraccumulationinthetumorthaninnormaltissues1-3.Variousnanoparticleshavebeenintensivelyusedasvehiclestodeliverchemotherapeutic

简介：Objective:Curativegastriccancersurgeryentailsremovaloftheprimarytumorwithadequatemarginsincludingregionallymphnodes.Europeanrandomizedcontrolledtrialswithrecruitmentinthe1990'sreportedincreasedmorbidityandmortalityforD2comparedtoD1.Here,weexaminedtheextentoflymphadenectomyduringgastriccancersurgeryandtheassociatedriskforpostoperativecomplicationsandmortalityusingthestrengthsofapopulation-basedstudy.Methods:AprospectivenationwidestudyconductedwithintheNationalRegisterofEsophagealandGastricCancer.AllpatientsinSwedenfrom2006to2013whounderwentgastriccancerresectionswithcurativeintentwereincluded.PatientswerecategorizedintoD0,D1,orD1+/D2,andanalyzedregardingpostoperativemorbidityandmortalityusingmultivariablelogisticregression.Results:Intotal,349(31.7%)patientshadaD0,494(44.9%)D1,and258(23.4%)D1+/D2lymphadenectomy.The30-dpostoperativecomplicationrateswere25.5%,25.1%and32.2%(D0,D1andD1+/D2,respectively),and90-dmortalityrateswere8.3%,4.3%and5.8%.Afteradjustmentforconfounders,inmultivariableanalysis,therewerenosignificantdifferencesinriskforpostoperativecomplicationsbetweenthelymphadenectomygroups.For90-dmortality,therewasalowerriskforD1vs.D0.Conclusions:ThemajorityofgastriccancerresectionsinSwedenhaveincludedonlyalimitedlymphadenectomy(D0andD1).Moreextensivelymphadenectomy(D1+/D2)seemedtohavenoimpactonpostoperativemorbidityormortality.

简介：目的：探讨人类微小RNA-141（has-miR-141）在子宫内膜癌患者血清中的表达及其临床意义。方法收集55例子宫内膜癌患者术前24h内的血清标本，以同期收治的12例子宫肌瘤患者术前24h内的血清和5例健康志愿者的血清作为对照组，应用实时荧光定量PCR技术检测子宫内膜癌患者和对照组血清中has-miR-141的表达水平，并分析has-miR-141表达水平与55例子宫内膜癌患者的临床病理危险因素的关系。结果子宫内膜癌患者的血清has-miR-141的表达水平（2.6295±2.038）高于对照组的（1.561±0.695），差异有统计学意义（P﹤0.05）。子宫内膜癌患者血清中has-miR-141表达与组织病理分型、淋巴结转移和临床分期诊断有关（P﹤0.05），非子宫内膜样癌、淋巴结转移、Ⅲ期＋Ⅳ期患者has-miR-141的表达水平高于子宫内膜样癌、无淋巴结转移、Ⅰ期＋Ⅱ期患者。不同组织病理分级、年龄、CA125值患者血清中has-miR-141的表达水平比较，差异无统计学意义（P﹥0.05）。结论子宫内膜癌患者血清中has-miR-141呈高表达水平，且与淋巴结转移、病理分型及临床分期有关。has-miR-141有可能成为一种诊断子宫内膜癌的新型标志物，同时有可能作为进展期子宫内膜癌的诊断依据，从而为子宫内膜癌的诊断及治疗提供有效帮助。

简介：

简介：Sincetheapprovalofrituximabin1997,monoclonalantibodies(mAbs)havebecomeanincreasinglyimportantcomponentoftherapeuticregimensinoncology.ThesuccessofmAbsasatherapeuticclassisaresultofgreatstridesthathavebeenmadeinmolecularbiologyandinbiotechnologyoverthepastseveraldecades.Currently,thereare14approvedmAbproductsforoncologyindications,andtherearetenadditionalmAbsinlatestagesofclinicaltrials.Comparedtotraditionalchemotherapeuticagents,mAbshaveseveraladvantages,includingalongcirculatinghalf-lifeandhightargetspecificity.Antibodiescanserveascytotoxicagentswhenadministeredalone,exertingapharmacologiceffectthroughseveralmechanismsinvolvingtheantigenbinding(Fab)and/orFcdomainsofthemolecule,andmAbsmayalsobeutilizedasdrugcarriers,targetingatoxicpayloadtocancercells.TheextremelyhighaffinityofmAbsfortheirtargets,whichisdesirablewithrespecttopharmacodynamics(i.e.,contributingtothehightherapeuticselectivityofmAb),oftenleadstocomplex,non-linear,target-mediatedpharmacokinetics.Inthisreport,wesummarizethepharmacokineticandpharmacodynamicsofmAbsthathavebeenapprovedandofmAbsthatarenearingapprovalforoncologyindications,withparticularfocusonthemolecularandcellularmechanismsresponsiblefortheirdispositionandefficacy.

简介：Risingworldwidecancerincidenceandresistancetocurrentanti-cancerdrugsnecessitatetheneedfornewpharmaceuticalcompoundsanddrugdeliverysystem.Malfunctionoftheimmunesystem,particularlyinthetumormicroenvironment,causestumorgrowthandenhancestumorprogression.Thus,cancerimmunotherapycanbeanappropriateapproachtoprovokethesystemicimmunesystemtocombattumorexpansion.Texosomes,whichareendogenousnanovesiclesreleasedbyalltumorcells,contributetocell-cellcommunicationandmodifythephenotypicfeaturesofrecipientcellsduetothetexosomes'abilitytotransportbiologicalcomponents.Forthisreason,texosome-baseddeliverysystemcanbeavaluablestrategyfortherapeuticpurposes.Toimprovethepharmaceuticalbehaviorofthissystemandtofacilitateitsuseinmedicalapplications,biotechnologyapproachesandmimetictechniqueshavebeenutilized.Inthisreview,wepresentthedevelopmenthistoryoftexosome-baseddeliverysystemsanddiscusstheadvantagesanddisadvantagesofeachsystem.

简介：

简介：Triple-negativebreastcancer(TNBC)isdiagnosedmorefrequentlyinyoungerandpremenopausalwomenandishighlyprevalentinAfricanAmericanwomen.TNBCisatermderivedfromtumorsthatarecharacterizedbytheabsenceofER,PgR,andHER2.SopatientswithTNBCdonotbenefitfromhormonalortrastuzumab-basedtherapies.TNBCsarebiologicallyaggressive,althoughsomereportssuggestthattheyrespondtochemotherapybetterthanothertypesofbreastcancer,prognosisremainspoor.Thisisdueto:shorteneddisease-freeintervalintheadjuvantandneoadjuvantsettingandamoreaggressivecourseinthemetastaticsetting.

简介：

简介：Iwashonoredtobeaskedtowriteaneditorialon’cytoreductivesurgeryusingperitonectomyandvisceralresectionsforperitonealsurfacemalignancy’(1)writtenbyPaulH.Sugarbaker.Astrategicapproachusingperitonectomyandcytoreductivesurgerytotreatperitonealcancershasgraduallyevolvedoverthepast30years

简介：

简介：Next-generationsequencing(NGS)hasbeenrapidlyintegratedintomolecularpathology,dramaticallyincreasingthebreadthgenomicofinformationavailabletooncologistsandtheirpatients.Thisreviewwillexplorethewaysinwhichthisnewtechnologyiscurrentlyappliedtobolstercareforpatientswithsolidtumorsandhematologicalmalignancies,focusingonpracticesandguidelinesforassessingthetechnicalvalidityandclinicalutilityofDNAvariantsidentifiedduringclinicalNGSoncologytesting.

简介：BackgroundSpinalpainisaserioushealthandsocial-economicproblem.Endoscopicspinesurgeryasatreatmentoptionforspinalpainhasgainedtremendousattentionandgrowthinthepast2decades,andavarietyofendoscopictechniqueshavebeeninventedtotreatawiderangeofspinalconditions.PurposesThepurposesofthis2-partreviewarticleareto1)overviewthepublishedtechniquesofendoscopicspinesurgery,2)summarizetheapplicationsofthesetechniquesintreatingvariousspinalconditions,and3)evaluatetheclinicalevidenceofthesafetyandeffectivenessoftheseendoscopictechniquesintreatingsomeofthemostcommonspinalconditions.Thefirstpartofthereviewarticleprovidesanoverviewofcurrentlymostcommonlyusedtechniques.MethodsWesearchedthePubMeddatabaseforpublicationsconcerningendoscopicspinesurgeryandreviewedtherelevantarticlespublishedintheEnglishlanguage.ResultsDiscectomyandforaminotomyarethemostcommontypesofspinesurgerythatcancurrentlybedoneendoscopically.Endoscopictechniqueshavebeenusedtotreatawiderangeofspinaldisorderslocatedinthelumbar,cervical,aswellasthethoracicregionsofthespine.

简介：Allogeneicstemcelltransplantation(allo-SCT)isapotentialcureforpatientswithmalignantlymphomathatisbasedonthegraft-versus-lymphoma(GVL)effect.Myeloablativeconditioningallo-SCTisassociatedwithhighmortalityandmorbidity,particularlyinpatientsolderthan45years,heavilypretreatedpatients(priorhematopoieticstemcelltransplantationormorethantwolinesofconventionalchemotherapy)orpatientsaffectedbyothercomorbidities.Therefore,conventionalallo-SCTisrestrictedtoyoungerpatients(<50to55years)ingoodphysicalcondition.Overthelastdecade,allo-SCTwithreduced-intensityconditioning(RIC-allo-SCT)hasbeenincreasinglyusedtotreatpatientswithlymphoma.Thistreatmentisassociatedwithlowertoxicityandsubstantialdecreaseintheincidenceoftransplant-relatedmortality,andhasthepotentialtoleadtolong-termremissions.Therefore,patientswhoarenotsuitabletoundergoconventionalallo-SCTcanbenefitfromthepotentiallycurativeGVLeffectsofallo-SCT.AlthoughRIC-allo-SCThasimprovedthesurvivaloflymphomapatients,highpost-transplantrelapseratesordiseaseprogressionmainlyresultsintreatmentfailure.Thus,furtherimprovementisclearlyneeded.TheroleandtimingofRIC-allo-SCTinthetreatmentoflymphomaremainsunclear.Therefore,moreprospectivestudiesshouldclarifytheeffectivenessofthismethod.Inthisarticle,wereviewtherecentliteratureonRIC-allo-SCTasatreatmentformajorlymphomasubtypes.Areasthatrequirefurtherinvestigationinthecontextofclinicaltrialsarealsohighlighted.

简介：

简介：Epithelialovariancancer(EOC)istheleadingcauseofdeathamongallgynecologicalmalignancies.Despitethetechnologicalandmedicaladvancesoverthepastfourdecades,suchasthedevelopmentofseveralbiologicalmarkers(mRNAandproteinsbiomarkers),themortalityrateofovariancancerremainsachallengebecauseofitslatediagnosis,whichisspecificallyattributedtolowspecificitiesandsensitivities.Underthiscompulsivescenario,recentadvancesinexpressionbiologyhaveshiftedinidentifyinganddevelopingspecificandsensitivebiomarkers,suchasmicroRNAs(miRNAs)forcancerdiagnosisandprognosis.MiRNAsareanovelclassofsmallnon-codingRNAsthatderegulategeneexpressionattheposttranscriptionallevel,eitherbytranslationalrepressionorbymRNAdegradation.Thesemechanismsmaybeinvolvedinacomplexcascadeofcellulareventsassociatedwiththepathophysiologyofmanytypesofcancer.MiRNAsareeasilydetectableintissueandbloodsamplesofcancerpatients.Therefore,miRNAsholdgoodpromiseaspotentialbiomarkersinovariancancer.Inthisreview,weattemptedtoprovideacomprehensiveprofileofkeymiRNAsinvolvedinovariancarcinomatoestablishmiRNAsasmorereliablenon-invasiveclinicalbiomarkersforearlydetectionofovariancancercomparedwithproteinandDNAbiomarkers.

简介：Objective:Langerhanscellhistiocytosis(LCH)hasbeenwelldescribedonlyinchildren.Weanalyzedthecharacteristics,reactivation,andoutcomeofLCHinacohortof55patientsacrossallages.Methods:WereviewedtherecordsofallpatientswithLCHtreatedatasingleinstitutebetweenJan.1974andMay1998.Results:The55patientswere2to67yearsofage(median,31years)atthetimeofdiagnosis,and85.5%weremale.Fortypatients(72.7%)hadsingle-systemLCH;Fifteen(27.3%)hadmultisystemdisease.Theheadandneckwasthemostfrequenttumorsite(63.6%).LCHwasnotfoundinorgansatriskofinvolvement(liver,spleen,bonemarrow,andlungs).Thefrequencyofbonyinvasion(23.6%overall)differedsignificantlyaccordingtoage(15years(66.7%)vs.Age>15years(11.6%)(P=0.0005).Atamedianfollow-upof12years,nopatientdiedofLCH.The5,10-yearsurvivalestimateswere100%.The5,10-yeardisease-freesurvivalestimateswere70.9%and58.4%.The5-yeardisease-freesurvivalestimatewas58.3%forage(15yearsvs.74.4%forage>15years(P=0.83)and75%forsingle-systemdiseasevs.60%formultisystemdisease(P=0.13).LCHwasreactivatedin43.6%ofpatients,withamedianof14months(range,2-180months).Threepatientswithrecurrentdiseaseexperiencedspontaneousremission.Atthetimeofthemostrecentfollow-up,23.6%ofsurvivorshadactivedisease.Conclusion:LCHisnotfoundexclusivelyinchildrenandadolescents.Thefrequencyofboneinvasionisinverselyrelatedtoage.Reactivationisverycommonregardlessofthetypeoftreatment,buttheprognosisisgenerallygood.

简介：Theimplementationofmolecularprofilingtechnologiesinoncologydeepensourknowledgeforthemolecularlandscapesofcancerdiagnoses,identifyingaberrationsthatcouldbelinkedwithspecifictherapeuticvulnerabilities.Inparticular,thereisanincreasinglistofmolecularlytargetedanticanceragentsundergoingclinicaldevelopmentthataimtoblockspecificmolecularaberrations.Thisleadstoaparadigmshift,withanincreasinglistofspecificaberrationsdictatingthetreatmentofpatientswithcancer.Thisparadigmshiftimpactsthefieldofclinicaltrials,sincetheclassicalapproachofhavingclinico-pathologicaldiseasecharacteristicsdictatingthepatients'enrolmentinoncologytrialsshiftstowardstheimplementationofmolecularprofilingasprescreeningstep.Inordertofacilitatethesuccessfulclinicaldevelopmentofthesenewanticancerdrugswithinspecificmolecularnichesofcancerdiagnoses,therehavebeendevelopednew,innovativetrialdesignsthatcouldbeclassifiedasfollows:i)longitudinalcohortstudiesthatimplement(ornot)'nested'downstreamtrials,2)studiesthatassesstheclinicalutilityofmolecularprofiling,3)'master'protocoltrials,iv)'basket'trials,v)trialsfollowinganadaptivedesign.Inthepresentarticle,wereviewtheseinnovativestudydesigns,providingrepresentativeexamplesfromeachcategoryandwediscussthechallengesthatstillneedtobeaddressedinthiseraofnewgenerationoncologytrialsimplementingmolecularprofiling.Emphasisisputonthefieldofbreastcancerclinicaltrials.

简介：

简介：OnbehalfoftheAmericanAssociationforCancerResearch(AACR),wehavethegreatpleasuretoinviteyoutoattendtheNewHorizonsinCancerResearchConference:DeliveringCuresThroughCancerScience,whichwillbeheldfromNovember2-5,2016,inShanghai,China.Thisthirdconferenceinthisserieshas,onceagain,beendesignedtohighlightsomeoftheverylatest